ASCRS 2024: Real-world results with an enhanced monovision toric lens


Josefina Botta, MD, MSc, discusses her real-world experiences with the RayOne EMV toric lens

Well, hello, everyone, I'm Dr Josefina Botta from Buenos Aires, Argentina, and today we're here in Boston, attending the ASCRS meeting. This year, it's been phenomenal. We had such a good turnout. I actually presented my real results using the RayOne EMV toric lens.

It's been really challenging to be able to present it here, for the American audience, not because they don't get with the message we're trying to deliver, but only because they don't have the lens yet. So I've been trying to introduce the lens for them. It's a real, really good lens; it's monofocal plus, that's a way we actually picture it to everyone. So we've been able to show results, show how stable the lens is in the bag. It doesn't rotate, the calculation is pretty accurate. And you're going to be able to give your patients real good distance vision, intermediate vision. And sometimes, when you play a bit with micromonovision or minimonovision, you're going to be able to deliver some functional near vision. So of course, we're not talking about a trifocal lens, but still very functional, very practical, from our point of view.

And also in correlation with what I'm just explaining, we will be working with the RayPRO platform, which is a digital platform that it's been created by Rayner, both for desktops and [as an app]. The only thing you need to do is to introduce your patient's email address, the type of lens you placed, it doesn't have to be a Rayner lens of course, because we're trying to be collaborative and work around with everyone. And we're very focused on their responses to the Cat-PROM5 questionnaire where they would answer what their experiences so we are very focused into the patient's experience. And we were able to actually come up with really good conclusions that we weren't expecting. Their number one complaint, the number one reason why they wouldn't be happy with our surgeries is because of dysphotopsias, and not much in relation to the use of glasses after surgeries.

We're going to be presenting these results in the upcoming ESCRS this year in Barcelona. So we hope to find you there and if there's any questions you may be able to contact myself or a member of our team. Thank you very much.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.